利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

270 条记录 (耗时 0.025 秒)

    Mesalamine suppository
    44.
    发明授权
    Mesalamine suppository 有权
    美沙胺栓剂

    公开(公告)号：US08217083B2

    公开(公告)日：2012-07-10

    申请号：US12476185

    申请日：2009-06-01

    申请人： Carl Gauthier ,  Yves Dumoulin ,  David Powell

    发明人： Carl Gauthier ,  Yves Dumoulin ,  David Powell

    IPC分类号： A01N33/02 ,  A01N37/36 ,  A01N37/12 ,  A01N37/44 ,  A61K31/135 ,  A61K31/60 ,  A61K31/195 ,  A61F13/00

    CPC分类号： A61K9/02 ,  A61K31/137 ,  A61K47/44 ,  Y10S514/953

    摘要： The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 400 to about 600 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 870 to about 1715 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP ) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.

    摘要翻译： 本发明涉及美沙拉坦直肠栓剂，其旨在提供改善的使用舒适性。 本发明的一个实施方案是美沙拉坦直肠栓剂，其包含美沙拉嗪和一种或多种药学上可接受的赋形剂，其中栓剂的药物负载范围为35％至50％。 本发明的另一个实施方案是美沙拉坦直肠栓剂，其包含约850至约1150mg美沙拉嗪和一种或多种药学上可接受的赋形剂，其中栓剂的总重量为约2250至约2700mg。 本发明的另一个实施方案是美沙拉坦直肠栓剂，其包含约400至约600mg的美沙拉嗪和一种或多种药学上可接受的赋形剂，其中栓剂的总重量为约870至约1715mg。 本发明的另一个实施方案是美沙拉坦直肠栓剂，其包含振荡密度范围为约600至约800g / L的美沙拉嗪（通过USP <616>测量）和具有上升熔点为32至35.5°的硬脂肪 C.还提供了制备方法和美沙拉嗪栓剂的治疗方法。 本发明还提供了一种通过用USP装置＃2在40℃下测量溶解参数（例如溶解度）来测定美沙拉嗪直肠栓剂如1g美沙胺栓剂的溶出参数（如溶出速率），并且桨叶转速 在pH 7.5的0.2M磷酸盐缓冲液中的125rpm。

    PROTEIN MATRIX MATERIALS, DEVICES AND METHODS OF MAKING AND USING THEREOF
    46.
    发明申请
    PROTEIN MATRIX MATERIALS, DEVICES AND METHODS OF MAKING AND USING THEREOF 有权
    蛋白质基质材料，其制备方法及其使用方法

    公开(公告)号：US20100196478A1

    公开(公告)日：2010-08-05

    申请号：US12700896

    申请日：2010-02-05

    申请人： David B. MASTERS

    发明人： David B. MASTERS

    IPC分类号： A61K9/10 ,  A61K38/16 ,  A61K35/00 ,  A61K38/43 ,  A61P17/02 ,  A61P43/00

    CPC分类号： A61K9/0024 ,  A61K9/0085 ,  A61K9/7007 ,  A61K47/42 ,  A61L27/227 ,  A61L27/54 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/602 ,  A61L2300/606 ,  A61L2300/622 ,  Y10S514/95 ,  Y10S514/953 ,  Y10S514/955 ,  Y10S514/964 ,  Y10S623/915 ,  C08L89/00

    摘要： The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents. The film is then partially dried, rolled or otherwise shaped, and then compressed to form the desired protein matrix device.

    摘要翻译： 本发明涉及蛋白质基质材料和装置，以及制备和使用蛋白质基质材料和装置的方法。 更具体地，本发明涉及可用于各种医学应用的蛋白质基质材料和装置，包括但不限于用于药理学活性剂的控制释放的药物递送装置，包封的或涂覆的支架装置，血管，管状移植物， 血管移植物，伤口愈合装置，包括蛋白质基质缝合材料和网眼，皮肤/骨/组织移植物，生物相容导电基质，透明蛋白质基质，蛋白质基质粘附防止屏障，细胞支架和其他生物相容性蛋白质基质装置。 此外，本发明涉及通过形成包含一种或多种可生物降解的蛋白质材料，一种或多种生物相容性溶剂和任选的一种或多种药理学活性剂的膜制备的蛋白质基质材料和装置。 然后将膜部分干燥，滚动或以其他方式成形，然后压缩以形成所需的蛋白质基质装置。

    Rapid acting drug delivery compositions
    47.
    发明授权
    Rapid acting drug delivery compositions 有权
    快速作用药物输送组合物

    公开(公告)号：US07279457B2

    公开(公告)日：2007-10-09

    申请号：US11077604

    申请日：2005-03-11

    申请人： Roderike Pohl ,  Solomon S. Steiner

    发明人： Roderike Pohl ,  Solomon S. Steiner

    IPC分类号： A61K38/28 ,  C07K16/00

    CPC分类号： A61K9/006 ,  A61K9/0019 ,  A61K9/0056 ,  A61K38/28 ,  Y10S514/866 ,  Y10S514/951 ,  Y10S514/953 ,  Y10S514/959

    摘要： Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.

    摘要翻译： 本文描述了具有改善的稳定性和快速起效的全身药物递送的药物制剂。 制剂可以通过口腔给药，舌下给药，肺部输送，鼻内给药，皮下给药，直肠给药，阴道给药或眼部给药来施用。 在优选的实施方案中，制剂是舌下给药或通过皮下注射给药。 制剂含有活性剂和一种或多种赋形剂，其被选择以增加溶解速率。 在优选的实施方案中，药物是胰岛素，赋形剂包括金属螯合剂如EDTA和酸如柠檬酸。 给药后，这些制剂在舌下施用时被口腔粘膜快速吸收，并且当通过皮下注射给药时，其迅速地被吸收到血液流中。 在一个实施方案中，组合物为干粉的形式。 在另一个实施方案中，组合物为薄膜，晶片，锭剂，胶囊或片剂的形式。 在第三个实施方案中，将干粉状胰岛素与含有药学上可接受的载体如水或盐水，金属螯合剂如EDTA和酸如柠檬酸的稀释剂混合。 还描述了用于储存和混合这些制剂的装置。

    Oral fluid absorbing compositions and system for application thereof in a method of dental arch treatment
    48.
    发明授权
    Oral fluid absorbing compositions and system for application thereof in a method of dental arch treatment 失效
    口腔液吸收组合物及其在牙弓治疗方法中的应用的系统

    公开(公告)号：US07029690B1

    公开(公告)日：2006-04-18

    申请号：US10288532

    申请日：2002-11-04

    申请人： Janet M. Wehrli

    发明人： Janet M. Wehrli

    IPC分类号： A61C5/00 ,  A61C5/04 ,  A61C15/00 ,  A61K7/16

    CPC分类号： A61C19/063 ,  Y10S514/835 ,  Y10S514/90 ,  Y10S514/902 ,  Y10S514/946 ,  Y10S514/953

    摘要： Disclosed are articles and oral compositions which enable positioning material(s) which absorb oral fluids into controlled, direct contact with at least one dental arch, or portion thereof, of a subject at the location where teeth emerge from dental arch gum tissue, in a manner conducive to increasing crevicular fluid flow while maintaining a relatively dry application field for a therapeutic and/or cosmetic result effecting period of time. The method is applicable to introduction of gingivally absorbed substances and to treatment of, for instance, periodontal gum disease wherein bacteria is swept along in the crevicular fluid and lysed.

    摘要翻译： 本发明公开了一种制品和口腔组合物，其能够将吸收口腔液体的定位材料定位成与牙科牙齿牙龈组织出现的位置处的受试者的至少一个牙弓或其部分直接接触， 有利于增加缝合液流动，同时保持相对干燥的施用场，用于治疗和/或美容结果影响一段时间。 该方法适用于引入牙龈吸收物质和治疗例如牙周病，其中细菌在裂缝液中被扫掠并裂解。

    Rapid acting drug delivery compositions
    50.
    发明申请
    Rapid acting drug delivery compositions 有权
    快速作用药物输送组合物

    公开(公告)号：US20050214251A1

    公开(公告)日：2005-09-29

    申请号：US11077604

    申请日：2005-03-11

    申请人： Roderike Pohl ,  Solomon Steiner

    发明人： Roderike Pohl ,  Solomon Steiner

    IPC分类号： A61K9/00 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K38/00 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  A61K38/22 ,  A61K38/23 ,  A61K38/26 ,  A61K38/27 ,  A61K38/28 ,  A61K38/29

    CPC分类号： A61K9/006 ,  A61K9/0019 ,  A61K9/0056 ,  A61K38/28 ,  Y10S514/866 ,  Y10S514/951 ,  Y10S514/953 ,  Y10S514/959

    摘要： Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.

    摘要翻译： 本文描述了具有改善的稳定性和快速起效的全身药物递送的药物制剂。 制剂可以通过口腔给药，舌下给药，肺部输送，鼻内给药，皮下给药，直肠给药，阴道给药或眼部给药来施用。 在优选的实施方案中，制剂是舌下给药或通过皮下注射给药。 制剂含有活性剂和一种或多种赋形剂，其被选择以增加溶解速率。 在优选的实施方案中，药物是胰岛素，赋形剂包括金属螯合剂如EDTA和酸如柠檬酸。 给药后，这些制剂在舌下施用时被口腔粘膜快速吸收，并且当通过皮下注射给药时，其迅速地被吸收到血液流中。 在一个实施方案中，组合物为干粉的形式。 在另一个实施方案中，组合物为薄膜，晶片，锭剂，胶囊或片剂的形式。 在第三个实施方案中，将干粉状胰岛素与含有药学上可接受的载体如水或盐水，金属螯合剂如EDTA和酸如柠檬酸的稀释剂混合。 还描述了用于储存和混合这些制剂的装置。